Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home | Suppliers

Discovery Innovation – Productive Partnering for Shared Success

Published 22 September 2011 | By Kinapse

Phase II clinical development has traditionally been considered the ‘sweet spot’ for big pharma partnering deals. However our recent analysis reveals that discovery and early-stage clinical alliances are of increasing importance to big pharma’s long-term business strategy. This paper highlights the shifting industry trends responsible for the growth in earlier-stage partnering and describes how key stakeholders in the discovery space are evolving. We discuss the implications of this changing landscape for big pharma, and outline the new competences required to maximize value, mitigate risks and ultimately deliver new treatments to market.

As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details

Help us to better improve our communications by entering all or some of the additional fields below, then click 'Download White Paper' to be taken to the next page.




Complete a quick security check and confirm terms and conditions

This step helps prevent unfair use of automated programs.
I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, or if you would prefer not to receive these, uncheck this box.
If you would prefer not to hear from carefully selected third party companies uncheck this box



By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory